** Shares of drugmaker ANI Pharmaceuticals ANIP.O rise 11.8% to $61 premarket
** Co reports Q4 revenue of $190.6 mln, beating analysts' average estimate of $175.4 mln, on strong demand for rare-disease drugs Iluvien and Yutiq - data compiled by LSEG
** Posts adj. Q4 profit of $1.63 per share vs estimates of $1.44
** Stock has fallen 8.9% in past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。